天境生物上涨9.92%，报2.88美元/股，总市值2.35亿美元

Core Insights - Tianjing Bio (IMAB) experienced a stock price increase of 9.92%, reaching $2.88 per share with a trading volume of $8.41 million and a total market capitalization of $235 million [1] Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1] - The company's net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, with the data sourced from NASDAQ [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [1] - The company aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, addressing unmet clinical needs and improving the quality of life for patients worldwide [1] - The mission of the company is to become a leading biopharmaceutical company rooted in China and oriented towards global markets [1]